Ornibel (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in Ornibel, is a combined hormonal contraceptive presented as a vaginal ring for intravaginal use. It works together with etonogestrel to prevent pregnancy by suppressing ovulation, thickening cervical mucus, and stabilizing the endometrium in women of reproductive age.

GNH USA supplies Ornibel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Ornibel, a combined hormonal contraceptive, is used to prevent pregnancy by acting on the reproductive hormonal pathway. - Contraception: prevents pregnancy in women of reproductive age. - Ovulation suppression: inhibits the mid‑cycle luteinizing hormone surge. - Endometrial alteration: maintains a thin endometrium to reduce the chance of implantation.

Ornibel may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient tension‑type headaches. - Breast tenderness: mild discomfort or swelling. - Irregular bleeding: spotting or breakthrough bleeding. - Mood changes: mild emotional fluctuations. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lung arteries. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe allergic reaction: anaphylaxis or angioedema. - Hepatic adenoma: benign liver tumor.

When prescribing Ornibel, clinicians should consider several safety precautions to minimise risk. - Contraindication: avoid in women with a history of thromboembolic disorders. - Smoking: do not use in women over 35 who smoke. - Cardiovascular disease: assess risk before initiating therapy. - Liver disease: use with caution in hepatic impairment. - Migraine with aura: contraindicated due to increased stroke risk. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Ornibel can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Antiepileptics: enzyme inducers (e.g., carbamazepine) may reduce hormone levels. - Rifampicin: decreases contraceptive efficacy. - St. John’s wort: herbal inducer that lowers hormone concentrations.

Moderate Interactions (Monitor Closely): - Antifungals: azoles (e.g., ketoconazole) may increase hormone levels. - Antibiotics: broad‑spectrum agents may have variable impact. - Protease inhibitors: may affect hormone metabolism. - Antidepressants: SSRIs may alter bleeding patterns.